Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency

Clinical and Experimental Immunology
H B NieburJ W Sleasman

Abstract

Multiple subcutaneous immunoglobulin (SCIG) products are available to treat primary antibody deficiency (PAD). The efficacy and tolerability of 16% SCIG (Vivaglobin(®) ) was compared with 20% SCIG (Hizentra(®) ) in PAD subjects. The study was a prospective, single-centre, open-label study of PAD subjects transitioning Vivaglobin to equivalent Hizentra doses, rounded to the nearest vial size. Comparisons included immunoglobulin (Ig)G levels; tetanus, varicella and Streptococcus pneumoniae titres; adverse events (AEs), annual infection rate and quality of life during 8 weeks of Vivaglobin and 24 weeks of Hizentra. Thirty-two subjects (aged 2-75 years) participated. Rounding to the nearest Hizentra vial size resulted in a 12·8% (± 2·9%) increase in SCIG dose. Median immunoglobulin (Ig)G level following 8 weeks of Vivaglobin was similar to 24 weeks of Hizentra (1050 versus 1035 mg/dl, respectively; P = 0·77). Both products had similar protective titres to tetanus, varicella and serotypes of S. pneumoniae, which were variable but well above protective levels. After 12 weeks of Hizentra, subjects reported fewer local site reactions compared with Vivaglobin. Switching products resulted in increased systemic AEs in some subjects but, o...Continue Reading

References

Sep 1, 1983·The Journal of Infectious Diseases·Z Shehab, P A Brunell
Jun 23, 2004·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Melvin Berger
Oct 14, 2004·The Journal of Allergy and Clinical Immunology·Ann GardulfMichael Borte
Jun 11, 2005·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Francisco A BonillaUNKNOWN Joint Council of Allergy, Asthma and Immunology
Dec 13, 2005·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Mark J AtkinsonSteven L Hass
Apr 4, 2006·The Journal of Allergy and Clinical Immunology·Jordan S OrangeUNKNOWN Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology
Jun 20, 2006·Journal of Clinical Immunology·Hans D OchsUNKNOWN Subcutaneous IgG Study Group
Oct 30, 2007·Clinical Immunology : the Official Journal of the Clinical Immunology Society·A GardulfUNKNOWN Vivaglobin Clinical Study Group
Dec 7, 2007·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Kenneth Paris, Ricardo U Sorensen
Apr 22, 2008·Immunology and Allergy Clinics of North America·Melvin Berger
Aug 30, 2008·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Meredith L Moore, James M Quinn
Oct 10, 2008·The Journal of Allergy and Clinical Immunology·Francisco A Bonilla
Oct 23, 2008·Immunology and Allergy Clinics of North America·Francisco A Bonilla
Nov 26, 2009·Biologicals : Journal of the International Association of Biological Standardization·Reinhard BolliPeter Lerch
Aug 3, 2010·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Jordan S OrangeMahlon M Wilkes
Jan 25, 2011·Biologicals : Journal of the International Association of Biological Standardization·Werner MaederReinhard Bolli
Mar 1, 2011·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Melvin BergerOthmar Zenker
May 11, 2011·Clinical Pharmacokinetics·Richard L WassermanJoseph A Church
May 18, 2011·Epilepsy & Behavior : E&B·Waleed M SweilehDonald E Morisky
Jun 28, 2011·Clinical Immunology : the Official Journal of the Clinical Immunology Society·S JollesB Grimbacher
Jul 11, 2012·Clinical and Experimental Immunology·J S OrangeB Grimbacher
Mar 5, 2013·Journal of Clinical Immunology·Melvin BergerJohn W Sleasman
Dec 11, 2013·Journal of Public Health Management and Practice : JPHMP·Laurence CohenDenise Koo

❮ Previous
Next ❯

Citations

Oct 26, 2016·The World Allergy Organization Journal·Marek L KowalskiTorsten Zuberbier
Dec 9, 2016·International Journal of Immunopathology and Pharmacology·Clementina CanessaChiara Azzari
Dec 10, 2019·Clinical Pharmacology in Drug Development·Mikhail A RojavinElie Haddad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.